Researchers from the New York State Department of Health found that current COVID-19 convalescent plasma guidelines may be allowing for sera with low neutralizing capacity to be administered.
Study authors measured serum cytokine levels of COVID-19 patients during the acute phase, and determined if IL-12 and IL-2 would be determinant of more severe disease progression.
Study authors estimated pre-exposure prophylaxis persistence among cohorts of patients with commercial vs Medicaid insurance.
Study authors identified a new tool to support pre-exposure prophylaxis adherence for HIV prevention, primarily in how adequate urine tenofovir levels measured in an immunoassay predicted HIV protection.
A few small studies conducted early in the SARS-CoV-2 pandemic observed radiological and pulmonary diffusion abnormalities among patients who had been discharged from the hospital for 3 months.
Study authors investigated the association between a brief, self-reported measure of engagement in HIV care and viral suppression outcomes.
Researchers aimed to estimate the prevalence of liver fibrosis and factors associated with it in people living with HIV compared with those in a control group.
Study authors assessed whether convalescent plasma with high SARS-CoV-2 antibody titers would prevent progression to severe disease in older patients with COVID-19 if administered within 72 hours after the onset of mild symptoms.
Study authors assessed whether prophylactic azithromycin can prevent worsening of lung function and reduce acute respiratory exacerbations in children with HCLD taking ART.
The Oxford-AstraZeneca COVID-19 vaccine, ChAdOx1, released 4 studies to analyze its efficacy in the prevention of mild, moderate, and severe COVID-19 infection; new studies also address rising concerns in the vaccine’s ability to protect against variants B.1.1.7 and B.1.351.
